NCT05966324View on ClinicalTrials.gov

Baxdrostat Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Japanese Population

PHASE1CompletedINTERVENTIONAL

Enrollment

41

Participants

Timeline

Start Date

July 5, 2022

Primary Completion Date

September 20, 2022

Study Completion Date

September 20, 2022

Conditions

Hypertension

Interventions

DRUG

baxdrostat

Baxdrostat is an aldosterone synthase inhibitor

Trial Locations (1)

92801

Anaheim Clinical Trials, Anaheim

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY